Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew Aju, Davidson Nancy E·Breast (Edinburgh, Scotland)
Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed and results have been presented over the last two years. These include tamoxifen for 5-10 years (ATLAS and aTTom), tamoxifen for 5 years followed by aromatase inhibitor (AI) for 5 years for women…